Dr. Federico Cappuzzo MD

Council Member Biography

Federico Cappuzzo, MD, is Professor and Vice Director of the Department of Medical Oncology at Humanitas Mirasole SPA in Milan, Italy. His main fields of interests include the treatment of lung cancer and colorectal cancer. Dr. Cappuzzo is involved in the development of new drugs such as irreversible tyrosine kinase inhibitors for the treatment of non-small cell lung cancer (NSCLC), leading to over 50 publications in peer reviewed journals. He discovered one of the most relevant mechanisms responsible for sensitivity to erlotinib and gefitinib in NSCLC (EGFR FISH testing), as well as the mechanism responsible for sensitivity to cetuximab in colorectal cancer (EGFR FISH testing). He is involved in several translational research studies looking at the mechanisms of resistance and sensitivity to targeted therapy. He has been involved in numerous clinical trials for newly developed therapeutic agents including Avastin, cetuximab, sorafenib, sunitinib, and zactima. (This is me - Update Profile)

Employment History

2006 - Unspecified

Vice Director , HUMANITAS MIRASOLE SPA